

## **Infection fatality rate of COVID-19 in community-dwelling populations with emphasis on the elderly: An overview**

**Running title: COVID-19 infection fatality rate in community-dwelling elderly**

Cathrine Axfors<sup>1</sup>, John P A Ioannidis<sup>1,2</sup> (0000-0003-3118-6859)

<sup>1</sup>Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA

<sup>2</sup>Departments of Medicine, of Epidemiology and Population Health, of Biomedical Data Science, and of Statistics, Stanford University, Stanford, California, USA

Correspondence to: John P A Ioannidis, Stanford Prevention Research Center, Medical School Office Building, Room X306, 1265 Welch Road, Stanford CA 94305, USA

Tel: 650-7045584; E-mail: [jioannid@stanford.edu](mailto:jioannid@stanford.edu)

Keywords: COVID-19; infection fatality rate; elderly

Word count: 5744

## ABSTRACT

**Objective:** This mixed design synthesis aimed to estimate the infection fatality rate (IFR) of Coronavirus Disease 2019 (COVID-19) in community-dwelling elderly populations and other age groups from seroprevalence studies. Protocol: <https://osf.io/47cgb>.

**Methods and analyses:** Eligible were seroprevalence studies done in 2020 and identified by any of four existing systematic reviews; with  $\geq 1000$  participants aged  $\geq 70$  years that presented seroprevalence in elderly people; that aimed to generate samples reflecting the general population; and whose location had available data on cumulative COVID-19 deaths in elderly (primary cutoff  $\geq 70$  years;  $\geq 65$  or  $\geq 60$  also eligible). We extracted the most fully adjusted (if unavailable, unadjusted) seroprevalence estimates. We also extracted age- and residence-stratified cumulative COVID-19 deaths (until 1 week after the seroprevalence sampling midpoint) from official reports, and population statistics, to calculate IFRs corrected for unmeasured antibody types. Sample size-weighted IFRs were estimated for countries with multiple estimates. Secondary analyses examined data on younger age strata from the same studies.

**Results:** Twenty-five seroprevalence surveys representing 14 countries were included. Across all countries, the median IFR in community-dwelling elderly and elderly overall was 2.9% (range 0.2%-6.9%) and 4.9% (range 0.2%-16.8%) without accounting for seroreversion (2.4% and 4.0%, respectively, accounting for 5% monthly seroreversion). Multiple sensitivity analyses yielded similar results. IFR was higher with larger proportions of people  $>85$  years. Younger age strata had low IFR values (median 0.0013%, 0.0088%, 0.021%, 0.042%, 0.14%, and 0.65%, at 0-19, 20-29, 30-39, 40-49, 50-59, and 60-69 years even without accounting for seroreversion).

**Conclusions:** The IFR of COVID-19 in community-dwelling elderly people is lower than previously reported. Very low IFRs were confirmed in the youngest populations.

## INTRODUCTION

Most Coronavirus Disease 2019 (COVID-19) affect the elderly (1), and persons living in nursing homes are particularly vulnerable (2). Hundreds of seroprevalence studies have been conducted in various populations, locations, and settings. These data have been used and synthesized in several published efforts to obtain estimates of the infection fatality rate (IFR, proportion of deceased among those infected), and its heterogeneity (3-6). All analyses identify very strong risk-gradient based on age, although absolute risk values still have substantial uncertainty. Importantly, the vast majority of seroprevalence studies include very few elderly people (7). Extrapolating from seroprevalence in younger to older age groups is tenuous. Elderly people may genuinely have different seroprevalence. Ideally, elderly should be more protected from exposure/infection than younger people, although probably the ability to protect the elderly has varied substantially across countries (8). Moreover, besides age, comorbidities and lower functional status markedly affects COVID-19 death risk (9, 10). Particularly elderly nursing home residents accounted for 30-70% of COVID-19 deaths in high-income countries in the first wave (2), despite comprising <1% of the population. IFR in nursing home residents has been estimated to as high as 25% (11). Not separating residents of nursing homes from the community-dwelling may provide an average that is too low for the former and too high for the latter. Moreover, ascertainment and reporting of COVID-19 cases and deaths in nursing home populations show considerable variation across countries (2), with potentially heavy bearing on overall mortality, while community-dwelling elderly data may be less unreliable (especially in high-income countries). Finally, seroprevalence estimates reflect typically community-dwelling populations (enrollment of nursing home residents is scarce/absent in serosurveys).

Here we estimated the COVID-19 IFR in community-dwelling populations at all locations where seroprevalence studies with many elderly individuals have been conducted. Primary emphasis

is on the IFR of the elderly. As a secondary analysis, we also explored the IFR of younger age-strata in these same studies.

## METHODS

### *Information sources*

We identified seroprevalence studies (peer-reviewed publications, official reports, or preprints) in four existing systematic reviews (3, 7, 12, 13) as for a previous project (14), using the most recent updates of these reviews and their respective databases as of November 23, 2021. All systematic reviews may miss some studies, despite their systematic efforts. In this project, the risk is minimized by using several existing systematic reviews of seroprevalence studies, each of them very meticulous. The protocol of this study was registered at the Open Science Framework (<https://osf.io/47cgb>) after piloting data availability in December 2020 but before extracting full data, communicating with local authorities and study authors for additional data and performing any calculations. Amendments to the protocol and their justification are described in Appendix Table 1.

### *Eligibility criteria*

We included studies on SARS-CoV-2 seroprevalence that had sampled at least 1000 participants aged  $\geq 70$  years in the location and/or setting of interest, provided an estimate of seroprevalence for elderly people, explicitly aimed to generate samples reflecting the general population, and were conducted at a location for which there is official data available on the proportion of cumulative COVID-19 deaths among elderly (with a cutoff placed between 60-70 years; e.g., eligible cutoffs were  $\geq 70$ ,  $\geq 65$ , or  $\geq 60$ , but not  $\geq 75$  or  $\geq 55$ ). Besides general population samples we also accepted studies focusing on patient cohorts (including residual clinical samples), insurance applicants, blood donors, and workers (excluding health care workers and others deemed to have higher than average exposure risk, since these would tend to overestimate seroprevalence). USA studies were excluded if they did not adjust seroprevalence for race or ethnicity, since these socio-economically related factors associate strongly with both study participation (15, 16) (blood donation, specific jobs, and insurance seeking) and COVID-19 burden (17-19). Following comments from peer-reviewers, we have added another exclusion criterion: crude seroprevalence being less than 1- test specificity and/or the 95% confidence interval of the seroprevalence going to 0% (since the seroprevalence estimate would be extremely uncertain). We focused on studies sampling participants in 2020, since IFRs in 2021 may be further affected by wide implementation of

vaccinations that may substantially decrease fatality risk and by other changes (new variants and better treatment). Following comments from peer-reviewers we also explored different eligibility criteria in two sensitivity analyses: (a) focusing only on explicitly general population samples based on the SeroTracker categories of “Household and community samples” and “Multiple general populations” and thus excluding for example patient cohorts, insurance applicants, blood donors, and workers, and (b) including only explicitly national-level general population studies without high risk of bias and with at least 500 participants aged  $\geq 70$  years. We applied the risk of bias assessments reported by the SeroTracker team (based on the Joanna Briggs Institute Critical Appraisal Tool for Prevalence Studies) (20). Two authors reviewed records for eligibility. Discrepancies were solved by discussion.

### ***Data extraction***

CA extracted each data point and JPAI independently verified the extracted data. Discrepancies were solved through discussion. For each location, we identified the age distribution of cumulative COVID-19 deaths and chose as primary age cutoff the one closest to 70, while placed between 60-70 years (e.g.,  $\geq 70$ ,  $\geq 65$ , or  $\geq 60$ ).

Similar to a previous project (3), we extracted from eligible studies information on location, recruitment and sampling strategy, dates of sample collection, sample size (overall and elderly group), and types of antibody measured (immunoglobulin G (IgG), IgM and IgA). We also extracted, for the elderly stratum, the estimated unadjusted seroprevalence, the most fully adjusted seroprevalence, and the factors considered for adjustment. Antibody titers may decline over time. E.g. a modelling study estimated 3-4 months average time to seroreversion (21). A repeated measurements study (22) suggests even 50% seroreversion within a month for asymptomatic/oligosymptomatic patients, although this may be an over-estimate due to initially false-positive antibody results. To address seroreversion, if there were multiple different time points of seroprevalence assessment, we selected the one with the highest seroprevalence estimate. If seroprevalence data were unavailable as defined by the primary cutoff, but with another eligible cutoff (e.g.,  $\geq 70$ ,  $\geq 65$ , or  $\geq 60$ ), we extracted data for that cut-off.

Population size (overall, and elderly) and numbers of nursing home residents for the location were obtained from multiple sources (see Appendix Table 2).

Cumulative COVID-19 deaths overall and in the elderly stratum (using the primary age cutoff) for the relevant location were extracted from official reports. The total number, i.e., confirmed and probable, was preferred whenever available. We extracted the accumulated deaths until 1 week after the midpoint of the seroprevalence study period (or the closest date with available data) to account for different delays in developing antibodies versus dying from infection (23, 24). If the seroprevalence study claimed strong arguments to use another time point or approach, while reporting official statistics on the number of COVID-19 deaths overall and in the elderly population, we extracted that number instead.

The proportion of cumulative COVID-19 deaths that occurred among nursing home residents for the relevant location and date was extracted from official sources or the International Long Term Care Policy Network (ILTCPN) report closest in time (2, 25). We defined community-dwelling individuals by excluding persons living in institutions. Types of institutions used for elderly in various countries differed in nature and in the frailty of individuals residing there. For each location, we extracted available definitions of institutions. We preferred numbers recorded per residence status, i.e., including COVID-19 deaths among nursing home residents occurring in hospital. If the latter were unavailable, we calculated the total number of deaths in nursing home residents with a correction (by multiplying with the median of available ratios of deaths in nursing homes to deaths of nursing home residents in the ILTCPN 10/14/2020 report (2) for countries in the same continent). We considered 95%, 98%, and 99% of nursing home residents' deaths to have occurred in people  $\geq 70$  years,  $\geq 65$  years and  $\geq 60$  years, respectively (26). For other imputations, see the online protocol.

### ***Missing data***

We communicated with the authors of the seroprevalence study and with officers responsible for compiling the relevant official reports to obtain missing information or when information was available but not for the preferred age cut-offs. Email requests were sent, with two reminders to non-responders.

### ***Calculated data variables***

*Infected and deceased community-dwelling elderly*

The number of infected people among the community dwelling elderly for the preferred date (1 week after the midpoint of the seroprevalence study period) was estimated by multiplying the adjusted estimate of seroprevalence and the population size in community-dwelling elderly. We preferred the most adjusted seroprevalence estimates. Following a suggestion from peer-reviewers, whenever no adjustment was made for test performance, we adjusted the estimates for test performance using the Gladen-Rogan formula (27). Moreover, we applied a non-prespecified correction for studies that excluded persons with diagnosed COVID-19 from sampling, primarily by using study authors' corrections, secondarily by adding the number of identified COVID-19 cases in community-dwelling elderly for the location up to the seroprevalence study midpoint.

The total number of fatalities in community-dwelling elderly was obtained by total number of fatalities in elderly minus those accounted for by nursing home residents in the elderly stratum. If the elderly proportion or nursing home residents' share of COVID-19 deaths were only available for another date than the preferred one, we assumed that the proportions were stable between the time points.

### *IFR estimation*

We present IFR with corrections for unmeasured antibodies (as previously described (3)) as well as uncorrected. When only one or two types of antibodies (among IgG, IgM, IgA) were used in the seroprevalence study, seroprevalence was corrected upwards (and inferred IFR downwards) by 10% for each non-measured antibody (28). We added a non-prespecified calculation of 95% confidence intervals (CIs) of IFRs based on extracted or calculated 95% CIs from seroprevalence estimates (Appendix Table 1). No further factors were introduced in the calculation. CI estimates should be seen with caution since they depend on adequacy of seroprevalence adjustments, and do not consider other types of uncertainty (e.g., regarding mortality statistics).

### *Synthesis of data*

Statistical analyses were done using R version 4.0.2 (29). Similar to a previous overview of IFR-estimating studies (3), we estimated the sample size-weighted IFR of community-dwelling elderly for each country and then estimated the median and range of IFRs across countries. As



expected, there was extreme heterogeneity among IFR estimates ( $I^2 = 99.2\%$ ), thus weighted meta-analysis averages are not meaningful (30, 31).

We explored a seroreversion correction of the IFR by  $X^m$ -fold, where  $m$  is the number of months from the peak of the first epidemic wave in the specific location and  $X$  is 0.99, 0.95, and 0.90 corresponding to 1%, 5%, and 10% relative monthly rate of seroreversion (21, 22, 32). We also added a non-prespecified sensitivity analysis to explore the percentage increase in the cumulative number of deaths and IFR, if the cutoff was put two weeks (rather than 1 week) after the study midpoint.

We expected IFR would be higher in locations with a higher share of people  $\geq 85$  years old among the analyzed elderly stratum. Estimates of  $\log_{10}IFR$  were plotted against the proportion of people  $\geq 85$  years old among the elderly (for population pyramid sources see Appendix Table 2).

#### *Added secondary analyses*

IFR in younger age-strata has become a very important question since we wrote the original protocol and the studies considered here offered a prime opportunity to assess IFR also in younger age strata. Among the included studies, whenever there were seroprevalence estimates and COVID-19 mortality data available for younger age groups, we complemented data extraction for all available age strata. Studies were excluded if no mortality data were available for any age stratum of maximum width 20 years and maximum age 70 years. We used the same time points as those selected for the elderly data. We included all age strata with a maximum width of 20 years and available COVID-19 mortality information. We corresponded the respective seroprevalence estimates for each age stratum with eligible mortality data. Consecutive strata of 1-5 years were merged to generate 10-year bins. For seroprevalence estimates we used the age strata that most fully covered the age bin for which mortality data were available; for the youngest age groups seroprevalence data from the closest available group with any sampled persons  $\leq 20$  years were accepted. E.g. for Ward et al (33), eligible age strata were 0-19 (paired with seroprevalence data for 20-24), 20-24, 25-34, 35-44, 45-54, 55-64. Population statistics for each analyzed age bin were obtained from the same sources as for the elderly. For age strata with multiple estimates from the same country, we calculated the sample size-weighted IFR per country before estimating median IFRs across locations for age groups 0-19, 20-29, 30-39, 40-49, 50-59, and 60-69 years. IFR estimates were placed in these age groups according to their midpoint, regardless of whether they

perfectly matched the age group or not, e.g. an IFR estimate for age 18-29 years was placed in the 20-29 years group. As for the main analysis, following a suggestion from peer-reviewers, whenever no adjustment was made for test performance, we adjusted the estimates for test performance using the Gladen-Rogan formula (27).

### ***Ethics approval***

Not applicable to this study.

### ***Patient and Public Involvement***

There was no involvement of patients nor the public in this research.

## **RESULTS**

### ***Seroprevalence studies***

By November 23, 2021, 3138 SARS-CoV-2 seroprevalence reports were available in the four systematic reviews. Screening and exclusions are shown in Appendix Figure 1 and Appendix Table 3. Twenty-four seroprevalence studies were included, one of which contained two separate surveys.

Table 1 shows for each eligible study the sampling period, sample size tested and positive, age cut-offs for the elderly group, antibody type(s), seroprevalence estimates, types of adjustments, number of deaths, and IFR estimates. The 25 seroprevalence surveys (Table 1) (33-57) represented 14 countries (Americas n=7, Asia n=3, Europe n=15). Only three studies were conducted in middle-income countries (one in Dominican Republic, two in India) and the other 22 in high-income countries. Seventeen studies targeted general population participants, 2 enrolled active or former blood donors, respectively (36, 40), 1 biobank participants (53), 1 hemodialysis patients (56), and 4 used residual blood samples (39, 50, 54, 55). Three studies excluded upfront persons with previously diagnosed COVID-19 from participating in their sample (46, 50, 57). Mid-sampling points ranged from April 2020 to December 2020. Sampling had a median length of 5.4 weeks (range 3 days to 5 months). The median number of elderly individuals tested was 1809 (range 1010-21953). Median seroprevalence was 3.5% (range 0.47%-25.2%). Adjusted seroprevalence estimates were available for 23/25 surveys.

### ***Mortality and population statistics***

COVID-19 deaths and population data among elderly at each location are shown in Table 1 (for sources, see Appendix Table 2). The proportion of a location's total COVID-19 deaths that happened among elderly had a median of 53% (range 51%-62%) in middle-income countries and 86% (range 51%-93%) in high-income countries. The proportion of a location's total COVID-19 deaths that occurred in nursing home residents was imputed for middle-income countries, and had a median of 43% (range 20%-85%) in high-income countries with available data (for Qatar, the number was imputed). One study (55) included only COVID-19 deaths that occurred in nursing homes and was corrected to reflect also the deaths among nursing home residents occurring in hospitals. Among the population, the elderly group comprised a median of 9% (range 6%-11%) in middle-income countries and 14% (range 0.6%-24%) in high-income countries. People residing in nursing homes were 0.08-0.20% of elderly in middle-income countries and a median of 4.8% (range 0.5%-12.8%) in high-income countries.

### ***Additional data contributed***

Additional information was obtained from authors and agencies on four studies for seroprevalence data (35, 38, 45, 56); three studies for mortality data (34, 35, 38); two studies for population data (34, 35); and five excluded studies (clarifying non-eligibility).

### ***Calculated IFRs***

For 6 countries with more than one IFR estimate available sample size-weighted average IFRs were calculated. In 14 countries, IFRs in community-dwelling elderly (Figure 1, Table 1) had a median of 2.9% (range 0.2%-6.9%). In two middle-income countries, IFR was 0.2% and 0.3%, versus a median of 3.1% (range 1.3%-6.8%) in 12 high-income countries. Figure 1 also shows 95% CIs for IFRs based on 95% CIs for seroprevalence estimates. For 9 studies, 95% CIs were direct extractions from the seroprevalence studies themselves, while complementary calculations were performed for the others as described in Appendix Table 1. For 8 studies, seroprevalence estimates were corrected for test performance using the Gladen-Rogan formula (Appendix Table 4). Median IFR in all elderly for all 14 individual countries was 4.9% (range 0.2%-16.8%). In the 2 middle-income countries, IFR in all elderly was 0.2% and 0.4% and in 12 high-income countries the median was 5.7% (range 2.1%-16.8%).

Sensitivity analyses exploring different rates of seroreversion appear in Appendix Table 5. For the scenario with 5% relative monthly seroreversion, median IFR in community-dwelling elderly was 2.4% (range 0.2%-5.9%) across all countries (0.1% and 0.3% in 2 middle-income countries, and 2.6% in 12 high-income countries); corresponding median IFR in all elderly was 4.0% (range 0.2%-14.8%). For the sensitivity analysis that explored the percentage increase in IFR if a later cutoff was used for cumulative deaths (two weeks after study midpoint), data were available for 22/25 seroprevalence surveys. There was a median relative increase of 4%, and median IFR in community-dwelling elderly became 3.0% (Appendix Table 6).

In additional analyses proposed by peer-reviewers, the median IFR was 2.9% when focusing only on explicitly general population samples (17 studies on 12 countries) and it was 3.1% among high-income countries (22 studies on 12 countries). The median IFR was 2.6% including explicitly national-level general population studies with at least 500 participants aged  $\geq 70$  years (18 studies on 13 countries) (screening and exclusions are shown in Appendix Figure 2). The median IFR was 2.8% upon excluding 4 studies where the selected time point with highest seroprevalence was not the latest available (seroprevalence had declined in the latest timepoint) (33, 36, 42, 54).

### ***IFR in the elderly and proportion $>85$ years***

There was steeply increasing IFR with larger proportions of people  $\geq 85$  years old (Figure 2). A regression of  $\log(\text{IFR})$  against the proportion of people  $\geq 85$  years old had a slope of 0.06 ( $p=0.002$ ), and suggested an IFR in community-dwelling elderly of 0.49%, 0.98%, and 3.90% when the proportion of people  $>85$  in the elderly group was 5%, 10%, and 20%, respectively.

### ***IFR in younger age-strata***

We could extract data and calculate IFR on another 97 age-strata observations from 21/25 seroprevalence surveys (three had no mortality data for any eligible non-elderly age stratum (34, 40, 46) and one sampled no individuals  $<65$  years of age (54)). The 21 surveys came from 12 countries. For the age group 0-19 years, only six studies had sampled participants for seroprevalence in the corresponding age group (33, 38, 39, 41, 49, 52); for the other studies, the closest available age group was used. Across all countries (Figure 3), the median IFR was 0.0013%, 0.0088%, 0.021%, 0.042%, 0.14%, and 0.65%, at 0-19, 20-29, 30-39, 40-49, 50-59, and 60-69 years, using data from all 12 countries for all age strata except 60-69, where data from 8 countries were used. Appendix Figure 3 visualizes these estimates against other, previously published evaluations of age-specific IFR.

## DISCUSSION

The IFR of COVID-19 in elderly was found to vary widely at locations where seroprevalence studies have enrolled many elderly individuals. IFR in community-dwelling elderly was consistently lower than in elderly overall, and in countries where nursing homes are widely used, the difference was very substantial. In secondary analyses, the aggregated estimates show very low IFR estimates for younger age groups.

Early estimates of case fatality rate (CFR, ratio of deaths divided by *documented* infections) in the elderly were very high and they played an instrumental role in disseminating both fear and alacrity in dealing with this serious pandemic. Early estimates of CFR from China (58) described CFR of 8% in the age group 70-79 and 14.8% in those  $\geq 80$  years. Extremely high CFR estimates were also reported initially from Italy (59) and New York (60). However, the number of infected individuals was much larger than the documented cases (61). Therefore, IFR is much lower than CFR. We are aware of three previous evaluations of age-stratified IFR estimates that combine seroprevalence data with age-specific COVID-19 mortality statistics (4, 5, 62). Whereas the current report is the only one to use the term “mixed-design” synthesis, also previous syntheses of IFRs using seroprevalence data are, by necessity, mixed-design, although decisions and calculations may not be as transparently disclosed. This work represents the only effort to date to synthesize data on age-stratified IFR estimates that uses a highly detailed prespecified and registered protocol, with addition of detailed justifications whenever further decisions had to be made. An exception is the secondary (non-prespecified) analysis of IFR in younger age groups; however, we argue that the eligibility criteria (consideration of large studies with  $>1000$  elderly individuals) are not likely to have introduced bias specifically for the IFR estimates in younger age groups.

Levin *et al* (4) is the basis for the US CDC pandemic planning scenarios (63). Levin *et al* report IFR 4.6% at age 75, and 15% at age 85 (4) without separating nursing home deaths (thus referring to all elderly). The assessment was based on relatively sparse data for these age groups and was limited to advanced economies. The authors counted deaths four weeks after the midpoint of the seroprevalence sampling period, which is the longest among the evaluations, with the argument that there is large potential reporting lag (although available mortality statistics are commonly updated retrospectively for the date of death). Also, almost all included studies came from hard-hit locations, where IFR may be substantially higher (3). Selection bias for studies with lower seroprevalence and/or higher death counts (6) may explain why their estimates for middle-aged and elderly are substantially higher than ours.

O'Driscoll *et al* (5) modeled 22 seroprevalence studies, and carefully comment how outbreaks in nursing homes can drive overall population IFRs. For young and middle-aged groups, their estimates largely agree with those presented here. Their estimates for elderly, which are reflecting the community-dwelling, are still higher than ours. For ages  $\geq 65$  years, their model uses data derived from one location (England) on deaths that did not occur in nursing homes and is validated against other locations with such statistics. This may overestimate the community-dwelling proportion, since deaths of nursing home residents occurring in hospitals are counted in the England community estimates. Conversely our evaluation adds granularity by using deaths in nursing home residents from many countries, and by using seroprevalence estimates from 25 serosurveys with many elderly individuals.

The Imperial College COVID-19 response team (62) presents much higher IFR estimates for elderly overall. They use a very narrowly selected subset of 10 studies in 9 countries, five of which had sampled  $>1000$  elderly people. Their selection criteria required  $>100$  deaths in the location at the

seroprevalence study midpoint, which skews the sample towards heavily-hit areas and higher IFRs (6).

Some published studies also present IFRs in elderly people for single locations based on seroprevalence data, but these are unavoidably location-limited (see Appendix text).

For persons 0-19 years, the median IFR was one death per 76,900 persons with COVID-19 infection, followed by estimates of 1:11,300 in ages 20-29, 1:4800 in ages 30-39, and 1:2400 in ages 40-49. The Imperial College study (62) has ~10 times higher estimates for persons 0-19 years and ~3 times higher for persons 20-29 years old; otherwise estimates in age groups <50 years are fairly consistent across previous (4, 5) and current analyses despite methodological differences.

Substantial true heterogeneity is very much expected since IFR is situation- and population-dependent. Both the age distribution and other characteristics of people within the elderly stratum vary between different countries. E.g., obesity is a major risk factor for poor outcome with COVID-19 infection and prevalence of obesity is only 4% in India versus 20-36% in high-income countries analyzed here. Besides differences in risk factor characteristics, documentation criteria for coding COVID-19 deaths may have varied non-trivially across countries. Under- and over-counting of COVID-19 deaths may have occurred even in countries with advanced health systems.

The observed differences in IFR between community-dwelling elderly and elderly overall is consistent with previous findings that beyond age, comorbid conditions and frailty are associated with higher COVID-19 mortality (e.g., (10)). Given that nursing home residents account for many COVID-19 deaths (64), a location's overall IFR across all ages is largely dependent on how nursing homes were afflicted (5). Spread in nursing homes was disproportionately high in the first wave (8). IFR in nursing home residents can be much higher than the IFR estimates we obtained for community-dwelling elderly. Seroprevalence studies of long-term care populations in Spain

(Madrid), northern Italy, UK and Brazil in early phases of the epidemic found prevalence of 55%, 41%, 33%, and 11.5%, respectively (65-69), i.e. several fold higher than the prevalence in the general community populations in these locations. Under-estimation of infections due to seroreversion may also be prominent in such studies (69). Large diversity in seroprevalence can exist between facilities, e.g. in the Brazil study (68) the seroprevalence was 100% and 76%, respectively in 2 nursing homes that had outbreaks and 0% or close to 0% in the other 13. The IFR in that study was 25% and this may be a reasonable estimate for nursing homes with rather debilitated frail populations, as corroborated also by other investigators (11). IFR may be much lower in facilities where residents are in overall good health and plan to spend many years of their life there; but extremely high in facilities that offer primarily palliative care.

The share of nursing home deaths decreased markedly over time (64) in most high-income countries with some exceptions (e.g. Australia). This change may be reflected in a much lower IFR among the elderly and the entire population after the first wave. Improved treatments (e.g. dexamethasone), and less use of harmful treatments (e.g. hydroxychloroquine, improper mechanical ventilation) may also have decreased IFR substantially in late 2020 and in 2021 (70, 71). Other investigators have estimated in 2020 a global IFR of only 0.11% in the absence of effects of new variants and vaccinations (72). Vaccines that are more effective in protecting against death rather than infection are also expected to have decreased the IFR in 2021. New variants becoming dominant in 2021 may also be associated with further lower IFR. E.g., in countries with extensive testing such as the UK, when the delta variant spread widely even CFR remained ~0.3% (73). Preliminary data on the omicron variant in late 2021 suggest that it may be associated with even lower severity (74).

Our analysis has several limitations. First, seroprevalence estimates among elderly reported by the included studies could over- or underestimate the proportion infected. We explored adjusted



estimates accounting for 1-10% relative seroreversion per month; however, higher seroreversion is likely (21, 22, 32). Higher seroreversion will affect more prominently studies carried out later in the pandemic. Also, the current estimates do not fully account for the unknown share of people who may have tackled the infection without generating detectable serum/plasma antibodies (e.g., by mucosal, innate, or cellular [T cell] immune mechanisms) (75-79). Sensitivity estimates for antibody assays typically use positive controls from symptomatic individuals with clinically manifest infection; sensitivity may be lower for asymptomatic infections. All seroprevalence studies may have substantial residual biases despite whatever adjustments, as is discussed in detail by one of us (JPAI) elsewhere, in terms of potential biases of different types of designs and sampling frames regarding representativeness against the general population (6). Even well-designed general population studies may specifically fail to reach and recruit highly vulnerable populations, e.g. disadvantaged groups, immigrants, homeless, and other people at high exposure risks and poor health. For studies carried out in the US, we prespecified an eligibility criterion to adjust for race/ethnicity, which we believe acts to mitigate related biases. Definitions and usage of race and ethnicity variables were expected to be too heterogeneous outside the US to introduce a common rule, which would exclude virtually all studies from non-US locations (as can be seen in Table 1, only one other study adjusts for ethnicity, one adjusts for nationality, and even other factors associated with socioeconomic position are scarce). The study by Paulino-Ramirez et al (41), in the Dominican Republic, specifically targeted “communities identified as emerging hotspots for SARS-CoV-2” for antibody testing, and should be mentioned specifically to have a risk of overestimating seroprevalence. This especially has relevance for generalizability of IFR to other middle-income countries, but has small bearing on the median IFR in the sample overall.

Second, the number of deaths may be biased for various reasons (3) leading to potential under- or over-counting. Among the countries included in this synthesis, others have pointed out concerns of underreporting of deaths specifically for India (e.g., (80)). Indeed, IFR estimates in India need to be seen with extra caution. A study in Madurai in south India found an IFR of 0.043% among people >15 years old, but estimated that given the age distribution the IFR should have been 9 times larger to match other countries (81). This could reflect under-reporting of deaths, lower rates of age-adjusted death risk in India, or both (82). For example, compared with USA and European countries, India has much lower proportions of obesity, diabetes, smoking, heart disease, medically maintained patients with terminal cancer, and medically immunosuppressed patients. These are all strong risk factors for fatality from COVID-19. Also of note, excess deaths in India in 2020-2021 may be much higher than the reported COVID-19 toll (83). However, excess deaths in a single year are notoriously difficult to calculate (especially in a country with suboptimal death registration) and reflect the composite of direct deaths due to COVID-19, indirect effects of the pandemic, direct and indirect effects of the measures taken and multiple other year- and country-specific causes (84, 85). Excess deaths should not be used to calculate IFR.

Of note, our estimates of IFRs for non-elderly young strata in India are not very dissimilar to those of high-income countries, while the divergence is much stronger in the elderly population. This may be further explained by the fact that among people >70 years old, the proportion of those who are >85 years old is only 9.5% in India, while it is much higher in high income countries (e.g. Spain 23.7%, Italy 21.1%). Moreover, the difference between India and high-income countries in prevalence of major comorbidities such as obesity that increase the risk of COVID-19 mortality is most prominent in the most elderly; in younger generations in India, the influence of western lifestyle is becoming more pervasive (86, 87). Therefore, the IFR in people >70 years old in India

may well be extremely lower than the respective figure in high-income countries. The same may apply also to other middle-income countries and also low-income countries.

To match the date for seroprevalence sampling (i.e., seroconversion) with cumulative deaths is an exercise with assumptions. Our sensitivity analysis that extended with one week the cutoff for counting deaths showed a negligible change in the median IFR calculation. Most studies included in our analysis had been performed during periods at or after the end of the first wave. Some studies performed sampling for several months, which introduces further uncertainty. However, typically the sampling covered periods with few fatalities, why the uncertainty about corresponding death counts and infection rates would arguably be small.

Third, we acknowledge the risk of bias in seroprevalence studies, mortality statistics, and even population statistics. However, assessments of risk of bias are far from straightforward, as illustrated by the discrepant assessments of these seroprevalence studies by other teams (6). It should be expected that estimates cited here have considerable uncertainty that is not accounted for in the presented 95% CIs, which were based solely on seroprevalence study sampling uncertainty (with potential adjustments). Others, e.g., Campbell and Gustafson (88), have proposed models that aim to take into account further sources of uncertainty. Overall, the strength of evidence regarding COVID-19 mortality has markedly improved since the early days of the pandemic, although some biases are still affecting currently available studies.

Fourth, even among high-income countries, our set of eligible surveys tends to include mostly data from countries with higher death rates, thus possibly also higher IFR. More prominently, our analysis includes limited data from Asia and no data from Africa. Consideration of age strata diminishes this representativeness bias, but cannot eliminate it. E.g., most countries not represented in the available data may have a shift towards lower ages within the stratum of the elderly. This

translates to lower IFR. Moreover, with the exception of India, all countries analyzed here have population prevalence of obesity 1.5-3-fold higher than the global prevalence (13%); other major risk factors for poor COVID-19 outcome such as smoking history, diabetes, cardiovascular disease, and immunosuppression (9) are also far more common in the high-income countries included in our analysis than the global average. Global IFR may thus be substantially lower in both the elderly and the lower age strata than estimates presented herein.

Fifth, as for previous syntheses of IFR based on seroprevalence data, many complementary pieces of information were needed beyond the systematic search for seroprevalence studies. Some of the decisions made in this process, e.g., the eligibility criterion of >1000 participants, could be described as arbitrary. This rule was introduced for feasibility and validity, since over a thousand of seroprevalence studies were available, the majority of which would be largely uninformative (given the huge uncertainty) even for the overall population, let alone the rarified subgroup of elderly persons. As we mention elsewhere, it tends to prefer studies done in populations with old age pyramids, and this may thus over-represent populations with many frail individuals who survive into late age with many comorbidities. Importantly, none of these rules were expected to introduce other overt biases, and they were set *a priori*.

This overview synthesis finds a consistently much lower IFR of COVID-19 in community-dwelling elderly than in elderly overall, a difference which is substantial in countries where nursing homes are an established form of residency. Very low IFR estimates were confirmed in younger groups (<50). For middle-aged groups and elderly, estimates were lower than in some previous influential work with biased methodological choices (4, 62), but in agreement with other work (5). The estimates presented here may serve as one of several key pieces of information underlying

public health policy decisions. With better management and better preventive measures hopefully IFR has already decreased further.

## **ACKNOWLEDGMENTS**

We thank sincerely Eva Heras Muxella, Cristina Royo-Cebrecos (Andorra), Sereina Herzog (Belgium), Ilse Peeters and Catharina Vernemmen at Sciensano, the Belgian Institute for Health (Belgium), Zoltán Vokó (Hungary), Peter Coyle, Laith Abu-Raddad (Qatar), for personal communication of seroprevalence and/or COVID-19 mortality statistics; and Giridhara D Babu, Rajesh Sundaresan, Siva Athreya (India), N. Ahmad Aziz, Monique M.B. Breteler (Germany), Public Health Scotland (Scotland), Office for National Statistics, Infection Survey Analysis (UK), Cesar Victora, Fernando Hartwig, Luis Vidaletti (Brazil) for personal communication to clarify non-eligibility. We thank the dedicated members of the SeroTracker and Worldometer teams as well as Wikipedia authors for their efforts to gather information on seroprevalence studies and COVID-19 mortality statistics.

## **DECLARATION OF INTERESTS**

All authors have completed the ICMJE uniform disclosure form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

## **ROLE OF THE FUNDING SOURCE**

No funding was received specifically for this work. Outside this work, the Meta-Research Innovation Center at Stanford (Stanford University) is supported by a grant from the Laura and John Arnold Foundation. Dr Axfors is supported by postdoctoral grants from the Knut and Alice Wallenberg Foundation, Uppsala University, the Swedish Society of Medicine, the Blanceflor Foundation, and the Sweden-America Foundation. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

## **DATA SHARING STATEMENT**

The protocol, data, and code used for this analysis will be made available at the Open Science Framework upon publication: <https://osf.io/47cgb>.

## **TRANSPARENCY STATEMENT**

The lead author affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned have been explained.

## **LICENSE STATEMENT**

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

## **CONTRIBUTOR STATEMENT**

The corresponding author attests that both listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Cathrine Axfors: Conceptualization, Methodology, Software, Formal analysis, Investigation, Data curation, Writing - original draft, Visualization, Project administration.

John P A Ioannidis: Conceptualization, Methodology, Formal analysis, Investigation, Data curation, Writing - review & editing, Visualization, Supervision.

## REFERENCES

1. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. *Environmental research*. 2020;188:109890.
2. Comas-Herrera A, Zalakaín J, Lemmon E, Henderson D, Litwin C, Hsu A, et al. Mortality associated with COVID-19 in care homes: international evidence. Article in LTCcovid.org, International Long-Term Care Policy Network, CPEC-LSE, 14 October 2020.
3. Ioannidis JPA. Infection fatality rate of COVID-19 inferred from seroprevalence data. *Bull World Health Organ*. 2021;99:19–33F.
4. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. *European journal of epidemiology*. 2020;35(12):1123-38.
5. O'Driscoll M, Dos Santos GR, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature*. 2020.
6. Ioannidis JPA. Reconciling estimates of global spread and infection fatality rates of COVID-19: An overview of systematic evaluations. *European journal of clinical investigation*. 2021;51(5):e13554.
7. Arora RK, Joseph A, Van Wyk J, Rocco S, Atmaja A, May E, et al. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. *Lancet Infect Dis*. 2020:S1473-3099(20)30631-9.
8. Ioannidis JPA. Precision shielding for COVID-19: metrics of assessment and feasibility of deployment. *BMJ global health*. 2021;6(1).
9. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020;584(7821):430-6.
10. Mak JKL, Kuja-Halkola R, Wang Y, Hägg S, Jylhävä J. Frailty and comorbidity in predicting community COVID-19 mortality in the U.K. Biobank: The effect of sampling. *J Am Geriatr Soc*. 2021;69(5):1128-39.
11. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *N Engl J Med*. 2020;382(22):2081-90.
12. Franceschi VB, Santos AS, Glaeser AB, Paiz JC, Caldana GD, Machado Lessa CL, et al. Population-based prevalence surveys during the Covid-19 pandemic: A systematic review. *Rev Med Virol*. 2020;n/a(n/a):e2200.
13. Chen X, Chen Z, Azman AS, Deng X, Sun R, Zhao Z, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. *The Lancet Global health*. 2021.
14. Ioannidis JPA. Precision shielding for COVID-19: metrics of assessment and feasibility of deployment. *medRxiv*. 2020:2020.11.01.20224147.
15. Patel EU, Bloch EM, Grabowski MK, Goel R, Lokhandwala PM, Brunner PAR, et al. Sociodemographic and behavioral characteristics associated with blood donation in the United States: a population-based study. *Transfusion*. 2019;59(9):2899-907.
16. Sohn H. Racial and Ethnic Disparities in Health Insurance Coverage: Dynamics of Gaining and Losing Coverage over the Life-Course. *Popul Res Policy Rev*. 2017;36(2):181-201.
17. Qeadan F, VanSant-Webb E, Tingey B, Rogers TN, Brooks E, Mensah NA, et al. Racial disparities in COVID-19 outcomes exist despite comparable Elixhauser comorbidity indices between Blacks, Hispanics, Native Americans, and Whites. *Scientific reports*. 2021;11(1):8738.



18. Ahmad F, Cisewski, JA, Miniño, A, Anderson, RN. Provisional Mortality Data - United States, 2020. *MMWR Morbidity and mortality weekly report*. 2021;70:519-22.
19. Xu JJ, Chen JT, Belin TR, Brookmeyer RS, Suchard MA, Ramirez CM. Racial and Ethnic Disparities in Years of Potential Life Lost Attributable to COVID-19 in the United States: An Analysis of 45 States and the District of Columbia. *International journal of environmental research and public health*. 2021;18(6).
20. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *International journal of evidence-based healthcare*. 2015;13(3):147-53.
21. Shioda K, Lau MSY, Kraay ANM, Nelson KN, Siegler AJ, Sullivan PS, et al. Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. *medRxiv*. 2020:2020.11.13.20231266.
22. Herrington D. Duration of SARS-CoV-2 Sero-Positivity in a Large Longitudinal Sero-Surveillance Cohort: The COVID-19 Community Research Partnership. *medRxiv*. 2021:2021.01.27.21250615.
23. Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. *PloS one*. 2020;15(12):e0244126-e.
24. Faes C, Abrams S, Van Beckhoven D, Meyfroidt G, Vlieghe E, Hens N, et al. Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients. *International journal of environmental research and public health*. 2020;17(20):7560.
25. Comas-Herrera A, Zalakaín J, Litwin C, Hsu A, Lemmon E, Henderson D, et al. Mortality associated with COVID-19 in care homes: early international evidence. Article in *LTCcovid.org*, International Long-Term Care Policy Network, CPEC-LSE, 26 June 2020.
26. Office for National Statistics. Deaths involving COVID-19 in the care sector, England and Wales [dataset] <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deaths-involving-covid-19-in-the-care-sector-england-and-wales>: Office for National Statistics; 2020 [updated July 3, 2020].
27. Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. *American journal of epidemiology*. 1978;107(1):71-6.
28. Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jiménez A, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. *Nat Commun*. 2020;11(1):3500-.
29. R Core Team. R: A language and environment for statistical computing. <https://www.R-project.org/>: Foundation for Statistical Computing, Vienna, Austria; 2020.
30. Ioannidis JP, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. *Bmj*. 2008;336(7658):1413-5.
31. Deeks J, Higgins J, Altman D. Analysing data and undertaking meta-analyses. Section 10.10 Heterogeneity. *Cochrane Handbook for Systematic Reviews of Interventions* version 62 (updated February 2021). [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook): Cochrane; 2021.
32. Pérez-Olmeda M, Saugar JM, Fernández-García A, Pérez-Gómez B, Pollán M, Avellón A, et al. Evolution of antibodies against SARS-CoV-2 over seven months: experience of the Nationwide Seroprevalence ENE-COVID Study in Spain. *medRxiv*. 2021:2021.03.11.21253142.

33. Ward H, Atchison C, Whitaker M, Ainslie KEC, Elliott J, Okell L, et al. Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults. medRxiv. 2020:2020.08.12.20173690.
34. Royo-Cebrecos C, Vilanova D, López J, Arroyo V, Francisco G, Pons M, et al. Res Sq. 2021.
35. Herzog S, De Bie J, Abrams S, Wouters I, Ekinçi E, Patteet L, et al. Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium – a serial prospective cross-sectional nationwide study of residual samples (March – October 2020). medRxiv. 2021:2020.06.08.20125179.
36. Saeed S, Drews SJ, Pambrun C, Yi QL, Osmond L, O'Brien SF. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada. Transfusion. 2021;61(3):862-72.
37. Tang X, Sharma A, Pasic M, Colwill K, Birnboim C, Nagelkerke N, et al. COVID Symptoms, Seroprevalence, and Mortality During the First Wave of SARS-CoV-2 in Canada. Available at SSRN: <https://dxdoiorg/102139/ssrn3752659>. 2021.
38. Public Health Ontario. COVID-19 Seroprevalence in Ontario: March 27, 2020 to June 30, 2020. <https://www.publichealthontario.ca/>. 2020.
39. Charlton CL, Nguyen LT, Bailey A, Fenton J, Plitt SS, Marohn C, et al. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic. Microbiology Spectrum. 2021;9(1):e00291-21.
40. Pedersen OB, Nissen J, Dinh KM, Schwinn M, Kaspersen KA, Boldsen JK, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Fatality Rate Among Elderly Danes: A Cross-sectional Study on Retired Blood Donors. Clin Infect Dis. 2020.
41. Paulino-Ramirez R, Báez AA, Vallejo Degaudenzi A, Tapia L. Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic. Am J Trop Med Hyg. 2020;103(6):2343-6.
42. Espenhain L, Tribler S, Sværke Jørgensen C, Holm Hansen C, Wolff Sönksen U, Ethelberg S. Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study. European journal of epidemiology. 2021;36(7):715-25.
43. Warszawski J, Meyer L, Franck J-E, Rahib D, Lydié N, Gosselin A, et al. Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV. medRxiv. 2021:2021.10.25.21265456.
44. Carrat F, de Lamballerie X, Rahib D, Blanché H, Lapidus N, Artaud F, et al. Seroprevalence of SARS-CoV-2 among adults in three regions of France following the lockdown and associated risk factors: a multicohort study. medRxiv. 2020:2020.09.16.20195693.
45. Merkely B, Szabó AJ, Kosztin A, Berényi E, Sebestyén A, Lengyel C, et al. Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary. GeroScience. 2020;42(4):1063-74.
46. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383(18):1724-34.
47. Murhekar M, Bhatnagar T, Selvaraju S, Rade K, Saravanakumar V, Vivian Thangaraj J, et al. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. Indian J Med Res. 2020;152(1):48-60.
48. Malani A, Ramachandran S, Tandel V, Parasa R, Sudharshini S, Prakash V, et al. SARS-CoV-2 Seroprevalence in Tamil Nadu in October-November 2020. medRxiv. 2021:2021.02.03.21250949.
49. Istat - Istituto Nazionale di Statistica, Ministero della Salute. PRIMI RISULTATI DELL'INDAGINE DI SIEROPREVALENZA SUL SARS-CoV-2. <https://www.istat.it/files/2020/08/ReportPrimiRisultatiIndagineSieropdf>. 2020-08-03.

50. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Al Kanaani Z, Al Khal A, Al Kuwari E, et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. *Scientific reports*. 2021;11(1):6233.
51. Coyle PV, Chemaitelly H, Hadj Kacem MAB, Al Molawi NHA, Kahlout RAE, Gilliani I, et al. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. *medRxiv*. 2021:2021.01.05.21249247.
52. Ministerio de Sanidad, III IdSC. ESTUDIO ENE-COVID: CUARTA RONDA. ESTUDIO NACIONAL DE SERO-EPIDEMIOLOGÍA DE LA INFECCIÓN POR SARS-COV-2 EN ESPAÑA. 15 DE DICIEMBRE DE 2020. <https://www.mscbs.gob.es/gabinetePrensa/notaPrensa/pdf/1512151220163348113pdf>; [https://portalcneisciies/enecovid19/informes/informe\\_cuarta\\_rondapdf](https://portalcneisciies/enecovid19/informes/informe_cuarta_rondapdf). 2021.
53. UK Biobank. UK Biobank SARS-CoV-2 Serology Study. 16th September 2020. <https://www.ukbiobank.ac.uk/>. 2020.
54. Public Health England, Joint Biosecurity Centre, NHS Test and Trace. Weekly Coronavirus Disease 2019 (COVID-19) Surveillance Report. Summary of COVID-19 surveillance systems. Year: 2020. Week: 32. <https://assets.publishing.service.gov.uk/>. 2020.
55. Hughes EC, Amat JAR, Haney J, Parr YA, Logan N, Palmateer N, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting. *J Infect Dis*. 2021;223(6):971-80.
56. Anand S, Montez-Rath M, Han J, Bozeman J, Kerschmann R, Beyer P, et al. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. *The Lancet*. 2020;396(10259):1335-44.
57. Kalish H, Klumpp-Thomas C, Hunsberger S, Baus HA, Fay MP, Siripong N, et al. Mapping a Pandemic: SARS-CoV-2 Seropositivity in the United States. *medRxiv*. 2021:2021.01.27.21250570.
58. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. *China CDC Weekly*. 2020;2(8): 113-122.
59. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA*. 2020;323(18):1775-6.
60. Thompson C, Baumgartner J, Pichardo C, et al. COVID-19 Outbreak - New York City, February 29-June 1, 2020. *MMWR Morbidity and mortality weekly report*. 2020;2020;69:1725–1729.
61. Bendavid E, Mulaney B, Sood N, Shah S, Bromley-Dulfano R, Lai C, et al. COVID-19 antibody seroprevalence in Santa Clara County, California. *International journal of epidemiology*. 2021.
62. Brazeau N, Verity R, Jenks S, et al. COVID-19 Infection Fatality Ratio: Estimates from Seroprevalence. Imperial College London. 2020-10-29.
63. United States Centers for Disease Control and Prevention. COVID-19 Pandemic Planning Scenarios 2021 [updated March 19, 2021. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html>.
64. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Second versus first wave of COVID-19 deaths: Shifts in age distribution and in nursing home fatalities. *Environmental research*. 2021;195:110856.
65. Candel FJ, Barreiro P, San Román J, Del Mar Carretero M, Sanz JC, Pérez-Abeledo M, et al. The demography and characteristics of SARS-CoV-2 seropositive residents and staff of nursing

- homes for older adults in the Community of Madrid: the SeroSOS study. Age and ageing. 2021;50(4):1038-47.
66. Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, et al. Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors. Journal of clinical medicine. 2020;9(9).
67. Krutikov M, Palmer T, Tut G, Fuller C, Shrotri M, Williams H, et al. Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study. The Lancet Healthy longevity. 2021;2(6):e362-e70.
68. Barros ENC, Valle APD, Braga PE, Viscondi JYK, Fonseca A, Vanni T, et al. COVID-19 in long-term care facilities in Brazil: serological survey in a post-outbreak setting. Revista do Instituto de Medicina Tropical de Sao Paulo. 2021;63:e10.
69. Krutikov M, Palmer T, Tut G, Fuller C, Azmi B, Giddings R, et al. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibody in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study. medRxiv. 2021:2021.09.27.21264166.
70. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. New Engl J Med. 2020;384(8):693-704.
71. Axfors C, Schmitt AM, Janiaud P, van 't Hooft J, Abd-Elsalam S, Abdo EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials. medRxiv. 2020:2020.09.16.20194571.
72. Ayoub HH, Mumtaz GR, Seedat S, Makhoul M, Chemaitelly H, Abu-Raddad LJ. Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. Glob Epidemiol. 2021;3:100068-.
73. Public Health England COVID-19 Epidemiology Cell. COVID-19 confirmed deaths in England (to 31 August 2021): report. Updated 12 October 2021. <https://www.gov.uk/government/publications/covid-19-reported-sars-cov-2-deaths-in-england/covid-19-confirmed-deaths-in-england-to-31-august-2021-report#case-fatality-risk>. 2021.
74. Imperial College COVID-19 response team, Ferguson N, Ghni A, Hinsley W, Volz E. Report 50: Hospitalization risk for Omicron cases in England. 22 December 2021. <https://doi.org/10.25561/930352021>.
75. Kikkert M. Innate Immune Evasion by Human Respiratory RNA Viruses. J Innate Immun. 2020;12(1):4-20.
76. Krammer F. The human antibody response to influenza A virus infection and vaccination. Nat Rev Immunol. 2019;19(6):383-97.
77. Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol. 2021;147(2):545-57.e9.
78. Gallais F, Velay A, Nazon C, Wendling M-J, Partisani M, Sibilia J, et al. Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France. Emerg Infect Dis. 2021;27(1):113.
79. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183(1):158-68.e14.

80. Deshmukh Y, Suraweera W, Tumbe C, Bhowmick A, Sharma S, Novosad P, et al. Excess mortality in India from June 2020 to June 2021 during the COVID pandemic: death registration, health facility deaths, and survey data. medRxiv. 2021:2021.07.20.21260872.
81. Laxminarayan R, B CM, G VT, Arjun Kumar KV, Wahl B, Lewnard JA. SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study. Lancet Infect Dis. 2021;21(12):1665-76.
82. Li Y, Nair H. How reliable are COVID-19 burden estimates for India? Lancet Infect Dis. 2021;21(12):1615-7.
83. Anand A, Sandefur J, Subramanian A. Three new estimates of India's all-cause excess mortality during the COVID-19 pandemic. Accessed in: <https://www.cgdev.org/publication/three-new-estimates-indias-all-cause-excess-mortality-during-covid-19-pandemic>. Last accessed, December 12, 2021: Center for Global Development, Working paper; 2021.
84. Kiang MV, Irizarry RA, Buckee CO, Balsari S. Every Body Counts: Measuring Mortality From the COVID-19 Pandemic. Annals of internal medicine. 2020;173(12):1004-7.
85. Ioannidis JPA. Over- and under-estimation of COVID-19 deaths. European journal of epidemiology. 2021;36(6):581-8.
86. Pradeepa R, Anjana RM, Joshi SR, Bhansali A, Deepa M, Joshi PP, et al. Prevalence of generalized & abdominal obesity in urban & rural India--the ICMR-INDIAB Study (Phase-I) [ICMR- NDIAB-3]. Indian J Med Res. 2015;142(2):139-50.
87. Luhar S, Timæus IM, Jones R, Cunningham S, Patel SA, Kinra S, et al. Forecasting the prevalence of overweight and obesity in India to 2040. PloS one. 2020;15(2):e0229438.
88. Campbell H, Gustafson P. Inferring the COVID-19 IFR with a simple Bayesian evidence synthesis of seroprevalence study data and imprecise mortality data. medRxiv. 2021:2021.05.12.21256975.

## FIGURE CAPTIONS

**Figure 1.** Infection fatality rates (IFRs) in elderly, corrected for unmeasured antibody types. **(A)** Countries' IFRs in community-dwelling elderly and elderly overall. **(B)** IFRs in community-dwelling elderly with 95% confidence intervals based on individual seroprevalence estimates and their uncertainty.

If multiple seroprevalence studies were available for the same country, we calculated the sample size-weighted IFR. As per above, the 95% CIs do not take into account other sources of uncertainty than those adjusted by the seroprevalence study authors (except adding an adjustment for test performance as per the Gladen-Rogan formula for those that had not already adjusted for test performance), and should be interpreted as conservative. Primarily, 95% confidence intervals are direct extractions from the seroprevalence studies. For studies that did not report 95% confidence intervals, we complemented with a calculation using the number of sampled and seropositive elderly individuals. For those that provided adjusted estimates for age brackets (e.g., 70-79, 80-89, and 90+), we combined estimates for each study using a fixed effects inverse variance meta-analysis (of arcsine transformed proportions) to obtain 95% CIs. Asymmetry to point estimates may be observed for these cases, since point estimates were calculated by multiplying age bracket seroprevalence by the corresponding population count (which is preferable, since it takes into account population distribution).

**Figure 2.** Infection fatality rate in community-dwelling elderly, corrected for unmeasured antibody types, plotted against the proportion of people  $\geq 85$  years old among the elderly.

Log<sub>10</sub> IFR: logarithm (with base 10) of the infection fatality rate. The “elderly” group is defined by the primary cutoff for each location. E.g. for Belgium 3% of the population is  $\geq 85$ , and 13.6% of the population is  $\geq 70$ , thus the proportion is 3/13.6. Imputation done for regional data: Denmark (3/5 regions), and Tamil Nadu, India, with country-level proportion of persons  $\geq 85$  years old among elderly.

**Figure 3.** Infection fatality rates in younger age groups derived from included seroprevalence studies.

IFRs are corrected for unmeasured antibody types. Sample size weighted IFRs were calculated for countries with multiple estimates available. \* Infinite values produced by zero death counts.

## TABLES

**Table 1.** Included seroprevalence studies with estimates of seroprevalence in the elderly, COVID-19 deaths in the elderly and community-dwelling elderly, and corrected infection fatality rate

Location (first author)	Recruitment strategy	Sampling period	Number tested; number positive (n)	Age cutoff for mortality; age cutoff for seroprevalence (years)	Antibody type(s)	Adjusted seroprevalence; crude seroprevalence (%)*	Adjustments	Deaths in community-dwelling elderly [all elderly] (n)	Population, community-dwelling elderly [all elderly] (n)	IFR community-dwelling elderly [all elderly] (%)
Andorra (Royo-Cebrecos)†	General	May 4 to May 28	4339; 582	70; 70	IgG/IgM	NaN; 14.92	None	22 [45]	7364 [7631]	1.84 [3.59]
Belgium (Herzog)	General	Mar 30 to Apr 5	1210; 29	70; 70	IgG	1.92; 2.4	Age, sex, province, test sensitivity and specificity	1057 [3317]	1453101 [1581078]	3.13 [9.03]
Canada (Saeed, Canadian Blood Services)	Blood donors	May 9 to July 21 (median date June 13)	9845; 74	70; 65	IgG	0.77; 0.75	Residential postal code, age, sex, sensitivity and specificity of the assay	890 [7477]	3577421 [3963155]	2.67 [20.25]
Canada (Ab-C Study Investigators)	General	June to August	1010; 14	70; 70	IgG	2.77; 1.39	Age, education levels	1299 [7823]	4112421 [4300000]	0.94 [5.43]
Alberta, Canada (Charlton)†	Residual blood samples	December 7 to December 10	2820; 29	70; 70	IgG	1.54; 1.54	None (crude)	213 [823]	289046 [326530]	3.97 [13.56]
Ontario, Canada (Public Health Ontario, COVID-19 Immunity Task Force)	General	June 5 to June 30	1236; 25	70; 70	IgG	1.92; 2.02	Population weighting and test characteristics	525 [2298]	1392596 [1513920]	1.62 [6.52]
Denmark (Espenhain)	General	Median date September 19, sampling	1473; NA	70; 65	IgG/IgM/IgA	1.5; NA	Test sensitivity and specificity	350 [565]	798797 [836716]	2.92 [4.5]

		period approx. 13 weeks								
Denmark (Pedersen)	Blood donors	June 2 to June 19	1201; 22	70; 70	IgG/IgM/IgA	1.4; 1.8	Sensitivity and specificity of the diagnostic assay; population size of recruitment areas (municipalities)	329 [531]	530764 [555882]	4.43 [6.82]
Dominican Republic (Paulino-Ramirez)†	General, hotspot areas	April to June	2739; 164	60; 60	IgG	NaN; 10.53	None	237 [282]	1156871 [1158933]	0.16 [0.19]
France (Warszawski, INSERM)†	General	Median date Nov 24, interquartile range Nov 18 to Dec 4	14531; 611	65; 65	IgG	5.05; 5.27	Sociodemographics, income, quality of contact information, population density, proportion of people below poverty line, age, gender, "departement", educational level, region	26958 [49488]	12902627 [13440786]	3.42 [6.03]
Ile-de-France, France (Carrat)	General	May 4 to June 23 (90% of tests were performed May 4 to May 24)	1394; 52	70; 70	IgG	4.73; 3.73	Age, sex, socio-professional category, test sensitivity and specificity	4297 [7712]	1279751 [1339192]	5.87 [10.07]
Nouvelle-Aquitaine, France (Carrat)	General	May 4 to June 23 (90% of tests were performed May 4 to May 24)	1765; 29	65; 65	IgG	1.7; 1.64	Age, sex, socio-professional category, test sensitivity and specificity	303 [409]	1406969 [1465885]	1.05 [1.36]
Hungary (Merkely)†	General	May 1 to May 16	1454; 9	70; 70	IgG	1.12; 0.93	"several area-, dwelling unit-, and individual-level auxiliary information", region, sex, age	248 [348]	1198425 [1249016]	1.53 [2.05]




Iceland (Gudbjartsson)	General	May 5 to June 12 (healthcare sample)	NA; NA	70; 70	IgG/IgM/IgA	0.47; NA	Region, sex, age	5 [7]	32782 [34865]	3.12 [4.23]
India (Murhekar)	General	August 19 to September 20	2768; 291	61; 61	IgG	6.2; 10.51	Sampling district, test performance	33655 [41386]	125239531 [125325806]	0.36 [0.44]
Tamil Nadu, India (Malani)	General	October 19 to November 30	1568; NA	70; 70	IgG	25.2; NA	Age, gender, test performance, district	3518 [4326]	4324266 [4328822]	0.27 [0.33]
Italy (ISTAT)	General	May 25 to July 15	NA; NA	70; 70	IgG	2.5; NA	Region, municipal type, gender, age group, employment status, municipal prevalence, percentage difference in municipal mortality rates compared to the same period of the previous year	19341 [29722]	10136455 [10400756]	6.31 [9.45]
Qatar (Abu-Raddad)†	Residual blood samples	May 12 to July 12 (median day June 28)	1809; 162	70; 70	IgG	13.29; 9.15	Sex, age, nationality	53 [65]	18166 [18247]	1.8 [2.21]
Spain (ISCI)†	General	November 16 to November 29	7526; NA	70; 70	IgG	7.88; NA	Province, sex, age, income	23335 [41681]	6512456 [6823002]	3.76 [6.41]
UK (NA)	Biobank	May 27 to Aug 14 (however monthly repeated sampling)	3956; NA	65; 70	Missing/Unclear	6.1; NA	Unclear	25678 [49669]	11917570 [12374961]	3.53 [6.58]
England (Ward)	General	June 20 to July 13	21953; 801	70; 65	IgG	3.25; 3.65	Test performance, age, sex, region, ethnicity, deprivation	22644 [41023]	7204057 [7556976]	8 [13.82]
England and Wales	Residual blood samples	May 1 to May 30	1702; NA	70; 70	Missing/Unclear	3.64; NA	Population-weighted adjusted	21063 [37838]	7665426 [8037210]	7.55 [12.94]

(Public Health England)										
Greater Glasgow and Clyde, Scotland (Hughes)	Residual blood samples	March 16 to May 24	2771; NA	70; 65	IgG	5.45; 8.23	Test performance, population-level dynamics, sex, age, care type, week of sample collection	295 [627]	188673 [195952]	2.37 [4.85]
USA (Anand)†	Hemodialysis	July (>80% in first 2 weeks)	13659; 1043	65; 65	IgG/IgM/IgA	8.09; 7.65	Age, sex, geographical region, race and ethnicity	51128 [111774]	52441191 [54058263]	1.2 [2.55]
USA (Kalish)	General, convenience	April 1 to August 2020 (>88% between May 10 and July 31)	1273; 46	65; 70	IgG/IgM/IgA	3.5; 3.61	Region, age, sex, race, ethnicity, urban/rural, children, education, homeowner, employment, health insurance, health-related questions, test performance	46571 [103862]	52441191 [54058263]	2.27 [4.42]
Netherlands (Vos)	General	June 9 to August 24; 90% enrolled by June 22	788; NA	70; 70	IgG	5; NA	Sex, age, ethnic background, degree of urbanization, test characteristics	2664 [5402]	2346731 [2451000]	1.88 [3.64]

Dominican Republic (Paulino-Ramirez): Number tested (n=2739) refers to individuals  $\geq 55$  years old, while number positive (n=164) refers to those  $\geq 60$  years old. France (INSERM): The total number of deaths in elderly is derived from their Tableau 4 (deaths occurring in hospital) and Tableau 2 (deaths in care homes). France (Carrat, Ile-de-France): see Appendix Table 2 for our calculation of deaths in elderly and community-dwelling elderly. Iceland (Gudbjartsson): Estimate is based on seroprevalence and PCR testing; persons previously diagnosed with COVID-19 did not enroll in the study. USA (Kalish): Excluded previously COVID-19-diagnosed persons from participating, why we added cases in community-dwelling elderly up to the study midpoint to the number of infected. UK (Hughes): COVID-19 death statistics for nursing home residents did not include deaths occurring in hospital, and so was corrected with a factor of 1.225 (the median of the ratio of deaths in nursing home residents / deaths occurring in nursing homes, in the European countries with such data in Comas-Herrera et al, International Long-Term Care Policy Network report, October 14). Netherlands (Vos): This study is only included in the sensitivity analysis that applied a  $\geq 500$  cutoff for the number of sampled elderly. NA: Not applicable (missing). \* Seroprevalence estimates not corrected for missing antibody types, unlike infection fatality rate estimates in this table. † Seroprevalence corrected for test performance with the Gladen-Rogan formula since the original source had not done so.

A



B

